共 879 条
[41]
Fecher LA(2019)Application of PD-1 blockade in cancer immunotherapy Comput Struct Biotechnol J 17 661-959
[42]
Flaherty KT(2015)Improved overall survival in melanoma with combined dabrafenib and trametinib New Engl J Med 372 30-581
[43]
Gershenwald JE(2015)Nivolumab in previously untreated melanoma without BRAF mutation N Engl J Med 372 320-1356
[44]
Hamid O(2015)rmott DF, Horak C, Jiang J, et al. Efficacy and safety of nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: a pooled analysis of 4 clinical trials JAMA Oncol 1 433-1546
[45]
Hong A(2016)Association of pembrolizumab with tumor response and survival among patients with advanced melanoma JAMA. 315 1600-1654
[46]
Kirkwood JM(2014)Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo J Immunol 194 950-1661
[47]
Lo S(2014)Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens Nature. 515 577-461
[48]
Margolin K(2017)Overall survival with combined nivolumab and ipilimumab in advanced melanoma N Engl J Med 377 1345-65
[49]
Messina J(2019)Five-year survival with combined nivolumab and ipilimumab in advanced melanoma N Engl J Med 381 1535-579
[50]
Postow MA(2018)Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma Nat Med 24 1649-2940